OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
12
Results
Show all
Save search
Copy query
Show results for
Unknown
(12)
Release Date
2016
(3)
2014
(3)
2013
(3)
2025
(1)
2024
(1)
2020
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
A targeted genetic association study of epithelial ovarian cancer susceptibility.
Not available
S-EPMC4884925
|
biostudies-literature
Cite
Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer.
Not available
S-EPMC4779669
|
biostudies-literature
Cite
Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
Not available
S-EPMC4082406
|
biostudies-literature
Cite
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
Not available
S-EPMC4000890
|
biostudies-literature
Cite
Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
Not available
S-EPMC3709460
|
biostudies-literature
Cite
Whole-genome sequencing of patients with rare diseases in a national health system.
Not available
S-EPMC7610553
|
biostudies-literature
Cite
Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10.
Not available
S-EPMC3946482
|
biostudies-literature
Cite
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.
Not available
S-EPMC3693183
|
biostudies-literature
Cite
Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
Not available
S-EPMC12535838
|
biostudies-literature
Cite
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Not available
S-EPMC4630206
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets